X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
FP-020 is a highly potent and selective oral MMP-12 inhibitor which is being investigated for the treatment of inflammatory and fibrotic diseases (idiopathic pulmonary fibrosis and sarcoidosis).
Lead Product(s): FP-020
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: FP-020
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 30, 2024
Details:
FP-001 (leuprolide mesylate), which is a Gonadotropin-releasing hormone receptor agonist. Currently, it is being evaluated in Phase III clinical trial studies with patients related to Central Precocious Puberty.
Lead Product(s): Leuprolide Mesylate
Therapeutic Area: Endocrinology Product Name: FP-001
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2024
Details:
FP-001 (leuprolide), a gonadotropin-releasing hormone (GnRH) agonist, is being developed for for the treatment of Central Precocious Puberty patients.
Lead Product(s): Leuprolide Mesylate
Therapeutic Area: Endocrinology Product Name: FP-001
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2023
Details:
The proceeds will be used to develop Camcevi, a leuprolide mesylate injection, in a Phase 3 trial for central precocious puberty, FP-045, an ALDH2 activator, in a Phase 1b/2 trial for Fanconi Anemia, and FP-025, an MMP-12 inhibitor, in a Phase 2 study for respiratory disease.
Lead Product(s): Leuprolide Mesylate
Therapeutic Area: Endocrinology Product Name: Camcevi
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $42.3 million Upfront Cash: Undisclosed
Deal Type: Financing June 27, 2023
Details:
Through this partnership with Foresee on the launch of CAMCEVI, Accord BioPharma with razor sharp focus on specialty pharmaceuticals, which will go beyond biology to bring more access to high-quality medicines to patients across the U.S.
Lead Product(s): Leuprolide Acetate
Therapeutic Area: Oncology Product Name: Camcevi
Highest Development Status: ApprovedProduct Type: Peptide
Recipient: Accord healthcare
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership April 04, 2022
Details:
Under the terms of this partnership, Foresee and TRPharm will collaborate to initially expedite the development of FP-045 in Fanconi Anemia. Turkey and the surrounding region has a high prevalence Fanconi Anemia as well as other rare diseases.
Lead Product(s): FP-045
Therapeutic Area: Rare Diseases and Disorders Product Name: FP-045
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: TRPharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 23, 2022
Details:
The randomised, double-blind, placebo-controlled, multi-centre study will assess the efficacy and safety of the highly selective FP-025. The subjects will be randomised in 1:1:1 ratio to receive FP-025 100mg or 300mg or placebo twice daily for 28 days.
Lead Product(s): FP-025
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: FP-025
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2021
Details:
The proceeds of the Public Offering will be used for supporting Foresee’s existing drug research and development programs – such as FP-025, for which a Phase II/III clinical trial IND application was recently submitted to the FDA for the treatment of ARDS in COVID-19 patients.
Lead Product(s): FP-025
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: FP-025
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $47.0 million Upfront Cash: Undisclosed
Deal Type: Financing December 24, 2020
Details:
GenScience Pharmaceuticals will get license for the commercialization of Foresee’s novel FP-001 program, Leuprolide Mesylate Injectable Suspension (LMIS) ready-to-use subcutaneous 6-month and 3-month depot formulations. The license agreement will cover the China market.
Lead Product(s): Leuprolide Mesylate
Therapeutic Area: Oncology Product Name: Camcevi
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: GenScience Pharmaceuticals
Deal Size: $124.0 million Upfront Cash: $8.0 million
Deal Type: Licensing Agreement November 17, 2020
Details:
FDA, in its Day-74 letter, stated that the New Drug Application (NDA) for CAMCEVI 42MG is sufficiently complete to permit a substantive review.
Lead Product(s): Leuprolide Mesylate
Therapeutic Area: Oncology Product Name: Camcevi
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 09, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
